Purpose: To examine gene expression differences between pre-and post-neoadjuvant systemic therapy (NST) specimens of breast cancers and identify biologic changers that may lead to new therapeutic insights.
Introduction
Neoadjuvant systemic therapy (NST) provides an opportunity to directly assess the chemotherapy sensitivity of breast cancer and also benefits patients with tumor down staging and lesser surgery (1) . Residual cancer volume after NST carries important prognostic information, and attaining a pathologic compete response (pCR: absence of invasive cancer in the breast and lymph nodes) heralds excellent long-term survival (2) (3) (4) (5) . Conversely, patients with residual cancer have variable prognosis. Some patients, particularly those with estrogen receptor (ER)-positive cancer, have good survival despite residual cancer, others, particularly those with triple receptor negative cancer, have poor prognosis if they have residual disease (3) (4) (5) . NST with anthracycline and/or taxane-containing regimens results in pCR rates between 6% and 30%, depending on tumor grade and receptor status (6) (7) (8) . Because of the clear association between residual cancer burden and survival, NST is an in vivo screen for efficacy of neoadjuvant chemotherapies. However, despite the well recognized poor prognosis of ER-and HER2-negative patients with residual cancer after neoadjuvant chemotherapy, no effective adjuvant therapy exists for this population.
One approach to increase treatment efficacy is to develop regimens that induce higher rates of pCR; the combination of trastuzumab and chemotherapy represents a successful example of this approach (9) . Another strategy could be to develop biologically targeted post-NST, adjuvant therapies that exploit the vulnerabilities of the residual cancer. Such approach will first require detailed molecular characterization of residual cancer and definition of targetable molecular pathways. The purpose of this analysis was to compare matched gene expression profiles of pretreatment cancer with residual cancer after NST. We assessed changes in molecular class defined by the PAM50 classifier; changes in ER, Ki67 [proliferating cell nuclear antigen (PCNA)], and HER2 status based on mRNA expression and also identified individual genes and gene sets that were differentially expressed between the matched specimens to define molecular pathways that seem to be enriched in post-NST residual cancer.
Materials and Methods

Patients and tumor tissues
Prechemotherapy fine needle aspirates (FNA) were collected in the context of a prospective biomarker discovery program conducted at MD Anderson Cancer Center. Matching postchemotherapy frozen surgical specimens were retrieved from the institutional tumor bank, patients with pCR were excluded from the search. We identified 25 cases with matching specimens, 21 of these patients received NST. The remaining 4 cases with matching FNA biopsy and surgical tissue without NST were used to estimate methodologic variability in repeat gene expression data from the same cancer. Patient characteristics for the 21 patients who received NST are in Supplementary Table S1 . The amount of residual cancer was determined by routine pathology examination of lumpectomy or mastectomy specimens. In addition, we also carried out molecular class prediction on paired FNA and core needle biopsies obtained during one biopsy session, without any intervening chemotherapy from 37 cancers to assess the sensitivity of the classification method to tissue sampling (10) . This research was approved by the Institutional Review Board, and all patients signed informed consent to allow biomarker studies to be carried out on their specimens.
RNA extraction and gene expression profiling
RNA was extracted from the FNA and surgical tumor samples using the RNAeasy Kit (Qiagen). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter), and they were considered adequate for further analysis if the optical density 260/280 ratio was 1.8 or more and the total RNA yield was 1 mg or more. cRNA generation, second-strand cDNA synthesis, and gene expression profiling with Affymetrix HG-U133A gene chips were done as described previously (10) (11) (12) . The 25 matching pre-post-NST gene expression data is available under GEO (Gene Expression Omnibus) accession number GSE 32072 and the 37 matching FNA and core biopsy data are available under accession number GSE 32518.
Data analysis
All gene expression data was normalized with MAS5 algorithm, mean centered to 600 and log 2 transformed before further analysis. We removed from further analysis probe sets with average expression values the lowest 25% to reduce noise from low expressed probe sets and also excluded stroma-related genes (n ¼ 1,618 probe sets; Supplementary Table S2 ) that were defined in a previous publication (10) . Stromal genes were removed from the analysis to minimize false discovery due to the different tissue composition of the pretreatment FNA and postchemotherapy surgically resected tissues (13) . Paired t test was used to identify differentially expressed genes between cohorts, and false discovery rates (FDR) were calculated by the Benjamini and Hochberg permutation method (14) . Differentially expressed genes were defined from the entire data set as well as from basal-like (n ¼ 9) and non-basal-like (n ¼ 12) cancers separately. The function of the differentially expressed genes was mapped to biologic pathways using the Ingenuity Pathway Analysis software (IPA, http:// www.ingenuity.com/). We also examined changes in the mRNA expression values of ESR1 ("205225_at") and ERBB2/HER2 ("212022_s_at") receptors and the proliferation markers Ki67 ("216836_s_at") and PCNA (201202_at). An ESR1 mRNA probe set expression value of more than 10.18 was considered as ER positive, and HER2 probe set expression value more than 12.54 was considered HER2 positive, on the basis of a previously established thresholds (10, 15) . Molecular class assignment was done by using the PAM50 method, briefly, we calculated Spearman's rank correlation between each sample and each subtype centroid and assigned the class of the most highly correlated centroid to each sample (16) . Six (ANLN, CDCA1, CXXC5, GPR160, TMEM45B, and UBE2T) of the 50 genes that are included in the PAM50 predictor could not be mapped to the Affymetrix HGU133A chip, the remaining 44 genes were used for molecular class prediction. PAM50 class concordance rate was calculated using the number of matched pairs that were assigned to the same subtypes
Translational Relevance
Neoadjuvant systemic therapy (NST) provides an opportunity to directly assess the therapy response in breast cancer. Residual cancer volume after NST carries important prognostic information. By examining gene expression differences between pre-and post-NST specimens of breast cancers, we could identify biologic changers that may lead to new therapeutic insights for a biologically resistant disease. By using gene expression data from prechemotherapy fine needle aspiration specimens and comparing them to surgically resected residual cancers, we found that expression of 200 to 600 probe sets changed between baseline and postchemotherapy samples and that energy metabolism-related processes are upregulated and immune-related signals are depleted in residual cancers. Targeting these biologic processes may represent promising adjuvant treatment strategies for patients with residual cancer.
divided by the total number of matched pairs. We also used gene set analysis (GSA) to assess changes in a priori defined gene set before and after chemotherapy (17) . In this analysis we included 235 canonical biologic pathways from IPA and 2 additional gene sets (Mego and colleagues, n ¼ 254 genes, Creighton and colleagues, n ¼ 230 genes) previously reported to be associated with residual disease after NST in breast cancer (Supplementary Table S3 ) (18, 19) . All analysis was done using BRB Array Tools v 4.1.0 (http:// linus.nci.nih.gov/BRB-ArrayTools.html) and R software v 2.7.2 (http://www.r-project.org; ref. 20) . Significance was estimated with permutation test (n ¼ 1,000). The null hypothesis was that the average degree of differential expression of members of a given gene set between the pre-and post-NST samples was the same as expected from a random set of genes of similar size.
Results
Changes in estrogen receptor and HER2 expression and proliferation measures
First, we assessed changes in individual molecules with therapeutic and prognostic relevance. Pre-and posttreatment ER and HER2 levels were highly correlated, the Spearman's rank correlation coefficients were R ¼ 0.706 and 0.836, respectively. The ER status before and after NST changed from ER-negative to ER-positive on one case and from ER-positive to ER-negative in another case (Fig. 1A) . HER2 status also changed in 2 cases in a similar manner (Fig. 1B) . Interestingly, among the HER2-negative (n ¼ 18) cancers, ERBB2 mRNA levels were slightly, but significantly, higher in the post-NST samples (P ¼ 0.011, unadjusted for multiple comparisons). However, this was not sufficient to alter HER2 status in any but one case, indicating relative stability and robustness of ER and HER2 status. The pre-and posttreatment expression levels of proliferation markers Ki67 and PCNA were moderately correlated, Spearman's rank correlation coefficients were R ¼ 0.301 and 0.395, respectively ( Fig. 1C and D ). There were no significant differences in proliferation measures between pre-and post-NST samples across all cases or when ER-positive and ER-negative cases were examined separately (data not shown). The ER, HER2, and Ki67 or PCNA expression levels did not change significantly in any of the 4 control specimens that received no NST.
Changes in molecular class before and after chemotherapy Next, we examined the stability of molecular class in the 21 pre-and post-NST specimens. Table 1 shows the class assignment of each sample including the correlation values to each reference class centroid (the larger the correlation coefficient, the greater similarity the sample has to a given centroid and class is determined by the largest coefficient). There were 8 cases in which the molecular subtype by PAM50 changed between pre-and postchemotherapy samples, corresponding to an overall concordance rate of 62%. Most of the time (6 of 8 samples), the change was to normal-like cancer in the post-NST sample; this was accompanied by an increase in the correlation coefficient for the normal-like centroid and decrease in the correlation to the original class centroid. In 3 cases the molecular class changed from basal-like to normal, in 2 cases from luminal A to normal, and in one case, each from HER2 enriched to normal. The residual cancer cellularity in many of these cases was low, 10%, 20%, and 30% (in 2 cases it remained relatively high 50% and 60%; Table 1 ). One case changed from HER2 enriched to luminal B and another from normal to basal-like. In 4 cases the changes in the correlation metrics were quite large, indicating substantial change in the gene expression pattern of the 44 genes that were used for classification. In the remaining cases, relatively small-scale changes in correlation values altered the class assignment that suggests less than ideal robustness of the class assignment method under these circumstances. When PAM50 was applied to the baseline FNA and the surgical specimen of the 4 control cases, there were no changes in the molecular subtype of the pairs. To further assess the effect of tissue sampling on molecular class assignment, we also applied the PAM50 predictor to 37 matching FNA and core biopsies that were collected simultaneously before any chemotherapy (10). Molecular class changed for the same tumor depending on sampling method in 6 cases, corresponding to an overall concordance rate of 83% (Supplementary Table S4 ). These observations indicated that alterations in tissue cellularity due to chemotherapy, or due to sampling method, can introduce substantial variability to molecular class prediction.
Enriched and depleted molecular pathways in residual cancers
To identify gene expression changes in residual cancer compared with pretreatment samples, we carried out paired sample t test on 15,062 probe for all cases (n ¼ 21) and also separately for the basal-like (n ¼ 9) and non-basal-like (n ¼ 12) cancers. When all cancers were analyzed together, 532 probe sets were differentially expressed between pre-and posttreatment samples at FDR 0.005 (corresponding to P 0.0003), 271 were overexpressed, and 261 were underexpressed in residual cancer relative to pretreatment samples (Supplementary Table S5 ). When only basal-like cancers were considered, 77 probe sets were overexpressed and 115 were underexpressed. In non-basal-like cancers the corresponding numbers were 149 and 135, respectively (Supplementary Table S5 ). To find out what molecular pathways may be affected by these transcriptional changes, we mapped the over-and underexpressed genes into biologic pathways by IPA. Table 2 lists the 10 canonical pathways that were up-or downregulated in the residual cancers. Results are presented for all cancers as well as for the basal-like and non-basal-like subsets. When cancers were analyzed without molecular stratification, the top 10 upregulated pathways in residual cancer included ER signaling and nuclear receptor signaling (e.g., PPAR signaling, PPARa/RXRa activation, Nur77 signaling in T lymphocytes, and aryl hydrocarbon receptor signaling), as well as the Notch and WNT signaling pathways. Pathways involved in hedgehog signaling, PI3K/AKT, ATM, and cell-cycle control were depleted in the residual cancers. It is likely that the different molecular subtypes of breast cancer may use different survival pathways or rely on distinct mechanisms of drug resistance and, therefore, we also conducted the same pathway analysis basal-like and non-basal-like breast cancers separately. Metabolic pathways (glutamate metabolism, chondroitin sulfate biosynthesis, and propanoate metabolism) were the most consistently upregulated in basal-like residual cancers; the other upregulated pathways were united by the key functional roles of increased phosphoinositide 3-kinase (PI3K), small G-protein, and calcium/calmodulin-dependent protein kinase II alpha (CAMK2) expression. Notch, hypoxia, and TNF and ILK signaling were upregulated in non-basal-like cancers. Sonic hedgehog signaling was consistently depleted in residual cancers in both molecular types, and the depletion of various immune-related pathways was particularly prominent in basal-like cancers (lipid antigen presentation by CD1, dendritic cell maturation, FC receptor-mediated phagocytosis and natural killer cell signaling).
To gain further insight into the molecular changes that occur in residual cancer specimens, we also carried out gene set analysis for 234 canonical biologic pathways and 2 gene signatures that were previously reported to be associated with residual disease after chemotherapy in breast cancer (18, 19) . When all cases were analyzed together 7 gene sets were overexpressed and 12 were underexpressed at P value 0.05 or less, in post-NST samples (Table 3) . When basal-like cancers were examined separately, again numerous metabolic pathways emerged as upregulated in residual cancers and various immune pathways dominated the downregulated gene sets. In non-basal-like cancers, 11 gene sets were overexpressed and 5 gene sets were underexpressed in post-NST (P 0.05). The results were broadly consistent with the pathways that were derived from differentially expressed genes. Fatty acid biosynthesis was the only common upregulated pathway in both basal-and non-basal-like residual cancers, and the sonic hedgehog signaling was the only common downregulated pathway (Table 3 , Fig. 2) . None of the 2 previously reported residual cancer-associated gene sets showed any significant enrichment before or after therapy in any disease subset (Supplementary Table S6 ). It has been suggested that the expression of genes involved with epithelial-mesenchymal transition (EMT) may be altered in cancers that survived chemotherapy (19) . To test this hypothesis, we compared the expression of 8 key EMT genes (CD44, PCNA, CDH1, SNAIL, SLUG, TWIST, SOX9, and TGFb) in pre-and post-NST samples. When all cancers (n ¼ 21) were examined together (Table 4) only SLUG, SOX9, and TWIST were significantly overexpressed (P ¼ 0.029, 0.001, and 0.004, respectively, unadjusted for multiple comparisons), and SNAI1 was significantly underexpressed (P ¼ 0.001) in post-NST samples. When basal-like and non-basal-like cancers were examined separately, CD44, SLUG SOX9, and TWIST were significantly overexpressed (P ¼ 0.012, 0.050, 0.010, and 0.028, respectively), and SNAI1 was significantly underexpressed (P ¼ 0.003) in residual post-NST non-basal-like cancers. In basal-like cancers no gene was significantly altered (Table 4 ).
Discussion
Our aim was to determine gene expression differences between primary tumor and corresponding residual cancer after NST. We conducted gene expression profiling on baseline FNAs and surgical resections from residual cancer after 4 to 6 months of cytotoxic chemotherapy. Any such analysis strategy is fraught not only by the limited number of tumors analyzed but also with technical challenges that increase the probability for false discovery. In our case, baseline biopsies were obtained with an FNA and residual cancers represented surgically resected tissues. Tissue sampling methods can have a profound effect on gene expression results from the same cancer (13) . Also, chemotherapy alters tumor cellularity in most cancers shifting tissue composition toward stromal and fibrotic components in post-NST samples (5) . These effects plus the inevitable technical noise in repeat gene expression profiling can mask real biologic changes in mRNA expression levels caused by NST in small studies. We tried to minimize tissue composition-related confounders by removing 1,618 probe sets that we previously found to be highly associated with tissue sampling and stromal "contamination" (10) . We also filtered the lowest expressed 25% of probe sets because these may be the most susceptible to technical noise in repeat measurements (21) . After controlling for these confounders, ER and HER2 status based on mRNA expression remained stable in all but 2 cases (10%). There were also no significant changes in 2 single gene proliferation metrics, the expression of Ki67 and PCNA. Conversely, molecular class changed in 8 cases (38%) mostly to normal-like subtype. This shift to normal-like in post-NST specimens was observed in cancers with the lowest cancer cell cellularity in residual disease and probably reflects a major shift in tumor composition. Because pretreatment FNAs contain mostly neoplastic cells and are devoid of stroma, our analysis is biased to detect increase in stromal components in the surgical specimens even after our best attempt to control for this variable (none of the PAM50 classifier genes were included in our stromal associated and therefore filtered gene list; ref. 22) . Nevertheless, these results indicate that molecular classification is susceptible to tissue sampling effects, and this should be considered when interpreting results from any repeat measurement of a tumor.
Using a stringent FDR threshold of 0.005, we found 200 to 600 probe sets differentially expressed between baseline and post-NST samples. When corresponding genes were mapped to biologic pathways, some interesting observations emerged. In basal-like cancers, pathways driven by PI3K, small G proteins, CAMK2, and several energy metabolism and biosynthetic pathways were enriched in post-NST samples, whereas immune cell-derived pathways and the sonic hedgehog pathway were depleted. The same broad picture emerged when gene set analysis was applied to the data. In non-basal-like breast cancers, notch signaling and also energy metabolism through fatty acid synthesis were upregulated and sonic hedgehog signaling as well as several immune-related pathways were depleted in residual cancers. However, due to the small sample size of this study, the variable cytotoxic therapies that these patients received and Figure 2 . Ingenuity Pathway Maps of the fatty acid biosynthesis gene set that was enriched in both the basal-like (A) and non-basal-like residual cancers (B) and the Sonic Hedgehog signaling gene set that was depleted in basal-like (C) as well as non-basal-like (D) residual cancers. Red, genes overexpressed in residual samples; green, genes underexpressed in residual samples; grey, genes with no statistically significant differential expression (P < 0.01); white, pathway member not available in data. Mixed colors represent variable association for the same gene depending on probe set (6.3.4.14, biotin carboxylase; 6.4.1.2, acetyl-CoA carboxylase).
the possible tissue sampling related confounders, these observations remain hypothesis generating until confirmed in repeated observations and in larger studies. We also note that in our analysis, we could not observe an increase in EMT-related features or cancer stem cell signatures in residual cancers, as suggested previously (18, 19) .
Two strong themes emerged from this analysis with potential therapeutic implications, the enrichment of energy-and metabolism-related processes in residual cancers that were most prominent in basal-like cancers and the depletion of immune-related signals. There is increasing interest in deciphering the deregulation of energy metabolism in cancer and attempts are being made to develop metabolism-targeted drugs (23) . Our data suggests that in response to cytotoxic therapy several metabolic pathways become upregulated in residual cancer tissue. We hypothesize that the increased metabolic activity may enable cells to survive treatment and targeting these processes may enhance the efficacy of standard chemotherapy regimens. It is also increasingly evident that the presence of immune cells in the tumor microenvironment carries prognostic value, particularly between ER-negative and highly proliferative ER-positive cancers, and is also associated with higher probability of pCR to NST (10, (24) (25) (26) . Because residual cancer tissue becomes depleted of immune-related transcriptional signals, probably due to the systematic immunosuppressive nature of chemotherapy, stimulating post-NST immune response may become a fruitful adjuvant therapeutic strategy for patients with residual cancer and high risk of recurrence. 
